Research Grade Amatuximab

Catalog No.

DHG52002

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Chimeric

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

CAK1 antigen, Mesothelin, MSLN, Pre-pro-megakaryocyte-potentiating factor, MPF

Concentration

1.77 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q13421

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MORAb-009, CAS: 931402-35-6

Clone ID

Amatuximab

Amatuximab and novel agents targeting mesothelin for solid tumors, PMID: 29184420

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?, PMID: 27863199

CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients, PMID: 29652548

Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection, PMID: 26898299

Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging, PMID: 25756664

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma, PMID: 25231400

The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model, PMID: 30333914

Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies, PMID: 26307499

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors, PMID: 25502863

Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model, PMID: 33905019

Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells, PMID: 33637083

[Systemic Treatment of Malignant Pleural Mesothelioma], PMID: 29361614

The role of mesothelin in tumor progression and targeted therapy, PMID: 22721387

Tumor-Shed Antigen Affects Antibody Tumor Targeting: Comparison of Two 89 Zr-Labeled Antibodies Directed against Shed or Nonshed Antigens, PMID: 29720923

Mesothelin targeted cancer immunotherapy, PMID: 17945478

Tackling Mesothelioma With Immunotherapies, PMID: 27510518

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors, PMID: 27853672

Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil, PMID: 27718761

Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights, PMID: 22787150

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin, PMID: 18088084

Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009, PMID: 22869130

Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers, PMID: 21037025

Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody, PMID: 21741258

Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma., PMID:39542119

Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity., PMID:38349311

Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies., PMID:37388728

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies., PMID:34885074

Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model., PMID:33905019

Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells., PMID:33637083

The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model., PMID:30333914

Tumor-Shed Antigen Affects Antibody Tumor Targeting: Comparison of Two 89Zr-Labeled Antibodies Directed against Shed or Nonshed Antigens., PMID:29720923

CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients., PMID:29652548

[Systemic Treatment of Malignant Pleural Mesothelioma]., PMID:29361614

Amatuximab and novel agents targeting mesothelin for solid tumors., PMID:29184420

Mesothelin Immunotherapy for Cancer: Ready for Prime Time?, PMID:27863199

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors., PMID:27853672

Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil., PMID:27718761

Tackling Mesothelioma With Immunotherapies., PMID:27510518

Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection., PMID:26898299

Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies., PMID:26307499

Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging., PMID:25756664

Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors., PMID:25502863

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma., PMID:25231400

Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009., PMID:22869130

Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights., PMID:22787150

The role of mesothelin in tumor progression and targeted therapy., PMID:22721387

Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody., PMID:21741258

Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers., PMID:21037025

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin., PMID:18088084

Mesothelin targeted cancer immunotherapy., PMID:17945478

Document Download

Research Grade Amatuximab.pdf